Cleveland Biolabs Inc. Completes Recruitment for Phase II Hormone-Refractory Prostate Cancer Trial

May 7, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BUFFALO, NY--(Marketwire - May 07, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), announced today that it has fully enrolled its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2